Bob Oliver Sells 30,250 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Bob Oliver sold 30,250 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the completion of the sale, the director owned 21,120 shares of the company’s stock, valued at $925,267.20. The trade was a 58.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Exelixis Trading Down 0.7%

Shares of NASDAQ EXEL opened at $44.16 on Friday. The firm has a market capitalization of $11.47 billion, a P/E ratio of 15.94, a P/E/G ratio of 1.00 and a beta of 0.42. The firm’s 50-day moving average price is $43.83 and its 200-day moving average price is $41.15. Exelixis, Inc. has a 1-year low of $32.38 and a 1-year high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business had revenue of $598.66 million during the quarter, compared to analyst estimates of $609.17 million. During the same period in the previous year, the company posted $0.55 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year. Equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

EXEL has been the subject of several research reports. Wall Street Zen downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Royal Bank Of Canada raised their price objective on shares of Exelixis from $45.00 to $46.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 11th. Citigroup downgraded shares of Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Wells Fargo & Company upped their target price on shares of Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Finally, Guggenheim downgraded Exelixis from a “buy” rating to a “neutral” rating in a research note on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Exelixis has an average rating of “Hold” and an average target price of $47.11.

Hedge Funds Weigh In On Exelixis

Hedge funds and other institutional investors have recently modified their holdings of the business. Van Diest Capital LLC bought a new position in shares of Exelixis in the fourth quarter valued at approximately $340,000. Invesco Ltd. boosted its position in Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock worth $265,379,000 after purchasing an additional 94,218 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Exelixis by 107.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 143,780 shares of the biotechnology company’s stock worth $6,302,000 after purchasing an additional 74,360 shares during the last quarter. Vident Advisory LLC grew its stake in Exelixis by 2.0% in the 4th quarter. Vident Advisory LLC now owns 153,901 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 3,085 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Exelixis during the 4th quarter valued at $1,003,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 earnings beat: Exelixis reported $0.94 EPS vs. $0.74 expected and showed y/y revenue growth (Q4 revenue $598.7M), which supports earnings momentum and margin strength. MarketBeat EXEL summary
• Positive Sentiment: Institutional / analyst backdrop is broadly constructive: multiple funds have added or increased stakes and several analysts have maintained or slightly raised targets (consensus target ~ $47.11), which leaves upside if execution/clinical data remain favorable. Analyst & institutional notes
• Neutral Sentiment: Short interest note appears anomalous — the reported February short interest shows 0 shares (short‑interest ratio 0.0 days), likely a data reporting artifact and not informative for positioning. (Source: short‑interest entry)
• Neutral Sentiment: Technical / valuation context: market cap ~ $11.5B, P/E ~16, 50‑day sma ≈ $43.8 and 200‑day sma ≈ $41 — the stock sits between short‑ and long‑term averages so momentum could swing with new catalysts. Key metrics
• Negative Sentiment: Large executive/insider selling this week: EVP Patrick Haley sold 67,814 shares (~$2.95M on Feb 17). Such large insider disposals can create negative optics about timing or liquidity needs. Haley SEC filing
• Negative Sentiment: Repeated CFO sales: Christopher Senner disclosed two sales (34,278 on Feb 13 and 30,617 on Feb 17) totaling roughly $2.8M, which amplifies negative insider‑selling optics. CFO SEC filings
• Negative Sentiment: Director-level reductions: Director Bob Oliver sold 30,250 shares (~$1.33M; ~59% reduction) and other insiders (SVP Brenda Hefti, Director Sue Eckhardt) also sold smaller blocks — combined insider sales this week approximate $8–9M, which likely pressured sentiment. Oliver SEC filing Hefti SEC filing Eckhardt SEC filing

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.